In a phase I/IIa study, the anti-LAG-3 antibody BMS-986016 was used in combination with nivolumab (NCT01968109) in patients with relapsed melanoma treated with anti-PD-1 antibodies. This evidence concerns the gene PDCD1 and melanoma.